Gougerot-Sjögren

Gougerot-Sjögren

Veille bibliograhique : Gougerot-Sjögren

Les articles sont classés du plus ancien au plus récent, n’hésitez pas à utiliser la barre de recherche pour filtrer les résultats par date par exemple.

Theander E et al. Prediction of Sjögren's Syndrome Years Before Diagnosis and Identification of Patients With Early Onset and Severe Disease Course by Autoantibody Profiling. Arthritis Rheumatol. 2015 Sep;67(9):2427-36 Lire le résumé
Nocturne G et al. Rheumatoid Factor and Disease Activity. Are Independent Predictors of Lymphoma in Primary Sjögren’s Syndrome. Arthritis Rheumatol Hoboken NJ. avr 2016;68(4):977‑85.Lire le résumé
Baer AN et al. Association of Anticentromere Antibodies. With More Severe Exocrine Glandular Dysfunction in Sjögren’s Syndrome: Analysis of the Sjögren’s. International Collaborative Clinical Alliance Cohort. Arthritis Care Res. oct 2016;68(10):1554‑9Lire le résumé
Bowman SJ et al. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren’s Syndrome. Arthritis Rheumatol Hoboken NJ. 2017 Jul;69(7):1440–50.Lire le résumé
Bootsma H et al. Editorial: Rituximab in the Treatment of Sjögren’s Syndrome: Is It the Right or Wrong Drug? Arthritis Rheumatol Hoboken NJ. 2017 Jul;69(7):1346–9.Lire le résumé
Bodewes ILA, Gottenberg J-E, van Helden-Meeuwsen CG, Mariette X, Versnel MA. Hydroxychloroquine
treatment downregulates systemic interferon activation in primary Sjögren’s syndrome in the JOQUER
randomized trial. Rheumatology [Internet]. 25 juin 2019 [cité 23 juill 2019]; Disponible sur:
https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/kez242/5523045
Lire le résumé
Felten R, Giannini M, Nespola B, Lannes B, Levy D, Seror R, et al. Refining myositis associated with primary Sjögren’s syndrome: data from the prospective cohort ASSESS. Rheumatology [Internet]. 11 août 2020 [cité 27 août 2020]Lire le résumé
Levy D, Nespola B, Giannini M, Felten R, Severac F, Varoquier C, et al. Significance of Sjögren’s syndrome and anti-cN1A antibody in myositis patients. Rheumatology [Internet]. 11 mai 2021 [cité 28 mai 2021]; Lire le résumé
Duret PM, Schleiss C, Kawka L, Meyer N, Ye T, Saraux A, et al. Bruton’s tyrosine kinase (BTK) gene overexpression is associated with risk of lymphoma in primary Sjögren’s syndrome. Arthritis Rheumatol Hoboken NJ. 28 avr 2023Lire le résumé
Xu D, Fang J, Zhang S, Huang C, Huang C, Qin L, et al. Efficacy and safety of telitacicept in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial. Rheumatol Oxf Engl. 3 juill 2023;kead265Lire le résumé
Mariette X, Barone F, Baldini C, Bootsma H, Clark KL, De Vita S, et al. A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome. JCI Insight. 8 déc 2022;7(23):e163030.Lire le résumé
De Frémont GM, Costedoat-Chalumeau N, Lazaro E, Belkhir R, Guettrot-Imbert G, Morel N, et al. Pregnancy outcomes in women with primary Sjögren’s syndrome: an analysis of data from the multicentre, prospective, GR2 study. Lancet Rheumatol. juin 2023;5(6):e330‑40.Lire le résumé
Dörner T, Kaul M, Szántó A, Tseng JC, Papas AS, Pylvaenaeinen I, et al. Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren’s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial. Ann Rheum Dis. 6 nov 2023;ard-2023-224691.Lire le résumé
Bettacchioli E, Saraux A, Tison A, Cornec D, Dueymes M, Foulquier N, et al. Combined anti‐Ro52/TRIM21 and anti‐Ro60/SSA antibodies are associated with increased Sjögren’s disease severity through interferon pathway activation. Arthritis Rheumatol. 21 déc 2023;art.42789.Lire le résumé